本帖最后由 老马 于 2013-3-13 13:43 编辑 ( q, w5 t/ Z+ C4 L* d6 W1 N" U
- K+ ]" O" h$ _5 s# R' X- Y0 P A6 H健择(吉西他滨)+顺铂+阿瓦斯汀
( @" A/ ~* b% s- h' T% @4 X Gemzar +Cisplatin + Avastin( o+ B8 B* g& k9 r/ K/ `; j
http://annonc.oxfordjournals.org/content/21/9/1804.full' R1 `) i5 `8 B" M4 S
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 t8 x1 Z: g" x$ f g1 n4 Z) IPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 6 w/ D' n5 I1 `9 J, C! u
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 3 B" l* |; C* g/ O; P
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 196)
8 T5 b& T0 Y# }3 h* V( }华为网盘附件:
% W+ ^0 v ]/ L% m* z【华为网盘】ava.JPG" b8 w6 p9 t$ d; q) D7 S
|